Lombard raises £1.6m, but only enough until end of 2008
This article was originally published in Clinica
Vascular stent graft developer Lombard Medical Technologies has raised £1.6m ($2.9m) – £1.4m after expenses – through a convertible note placement, but said the funds will not be enough for it to continue trading beyond January 2009. The London, UK-based company said that the new cash will give it the "breathing space" it requires, while it tries to secure additional funding for its long-term needs. The firm is currently in talks with a number of parties, including a "significant Middle Eastern bank" that has expressed an interest in investing up to $15m in Lombard through equity.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.